Close Menu

NEW YORK – In vitro diagnostics maker PathogenDx is positioning its microarray-based testing system to target the clinical lab market. The Scottsdale, Arizona-based firm recently received funding from the National Institutes of Health's Rapid Acceleration of Diagnostics, or RADx, initiative to scale up its COVID-19 testing, and the firm expects to launch a clinical diagnostic test as soon as it receives Emergency Use Authorization from the US Food and Drug Administration.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.